Literature DB >> 12663508

Permanent hair dyes and bladder cancer: risk modification by cytochrome P4501A2 and N-acetyltransferases 1 and 2.

Manuela Gago-Dominguez1, Douglas A Bell, Mary A Watson, Jian-Min Yuan, J Esteban Castelao, David W Hein, Kenneth K Chan, Gerhard A Coetzee, Ronald K Ross, Mimi C Yu.   

Abstract

We have previously reported permanent hair dye use to be a significant risk factor for bladder cancer in US women. We also have examined N-acetyltransferase-2 (NAT2) phenotype in relation to the hair dye-bladder cancer relationship, and found that the association is principally confined to NAT2 slow acetylators. In the present study, we assessed the possible modifying effects of a series of potential arylamine-metabolizing genotypes/phenotypes (GSTM1, GSTT1, GSTP1, NAT1, NAT2, CYP1A2) on the permanent hair dye-bladder cancer association, among female participants (159 cases, 164 controls) of the Los Angeles Bladder Cancer Study. Among NAT2 slow acetylators, exclusive permanent hair dye use was associated with a 2.9-fold increased risk of bladder cancer (95% CI = 1.2-7.5). The corresponding relative risk in NAT2 rapid acetylators was 1.3 (95% CI = 0.6-2.8). Frequency- and duration-related dose-response relationships confined to NAT2 slow acetylators were all positive and statistically significant. No such associations were noted among NAT2 rapid acetylators. Among CYP1A2 'slow' individuals, exclusive permanent hair dye use was associated with a 2.5-fold increased risk of bladder cancer (95% CI = 1.04-6.1). The corresponding risk in CYP1A2 'rapid' individuals was 1.3 (95% CI = 0.6-2.7). Frequency- and duration-related dose-response relationships confined to CYP1A2 'slow' individuals were all positive and statistically significant. No such associations were noted among CYP1A2 'rapid' individuals. Among lifelong non-smoking women, individuals exhibiting the non-NAT1*10 genotype showed a statistically significant increase in bladder cancer risk associated with exclusive permanent hair dye use (OR = 6.8, 95% CI = 1.7-27.4). The comparable OR in individuals with the NAT1*10 genotype was 1.0 (95%CI = 0.2-4.3). Similarly, all frequency- and duration-related dose-response relationships confined to individuals possessing the non-NAT1*10 genotype were positive and statistically significant. On the other hand, individuals of NAT1*10 genotype exhibited no such associations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663508     DOI: 10.1093/carcin/24.3.483

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  34 in total

1.  NATb/NAT1*4 promotes greater arylamine N-acetyltransferase 1 mediated DNA adducts and mutations than NATa/NAT1*4 following exposure to 4-aminobiphenyl.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Mol Carcinog       Date:  2011-08-11       Impact factor: 4.784

2.  Phenotype of the most common "slow acetylator" arylamine N-acetyltransferase 1 genetic variant (NAT1*14B) is substrate-dependent.

Authors:  Lori M Millner; Mark A Doll; Jian Cai; J Christopher States; David W Hein
Journal:  Drug Metab Dispos       Date:  2011-10-18       Impact factor: 3.922

3.  Hair dye use and risk of bladder cancer in the New England bladder cancer study.

Authors:  Stella Koutros; Debra T Silverman; Dalsu Baris; Shelia Hoar Zahm; Lindsay M Morton; Joanne S Colt; David W Hein; Lee E Moore; Alison Johnson; Molly Schwenn; Sai Cherala; Alan Schned; Mark A Doll; Nathaniel Rothman; Margaret R Karagas
Journal:  Int J Cancer       Date:  2011-08-12       Impact factor: 7.396

4.  The influence of aging, environmental exposures and local sequence features on the variation of DNA methylation in blood.

Authors:  Scott M Langevin; E Andres Houseman; Brock C Christensen; John K Wiencke; Heather H Nelson; Margaret R Karagas; Carmen J Marsit; Karl T Kelsey
Journal:  Epigenetics       Date:  2011-07-01       Impact factor: 4.528

5.  Susceptibility of XPD and RAD51 genetic variants to carcinoma of urinary bladder in North Indian population.

Authors:  Ranbir Chander Sobti; Saranjeet Kaur; Vijay Lakshmi Sharma; Shrawan Kumar Singh; Seyed Ali Hosseini; Rupinder Kler
Journal:  DNA Cell Biol       Date:  2011-07-08       Impact factor: 3.311

6.  Beauty product-related exposures and childhood brain tumors in seven countries: results from the SEARCH International Brain Tumor Study.

Authors:  J T Efird; E A Holly; S Cordier; B A Mueller; F Lubin; G Filippini; R Peris-Bonet; M McCredie; A Arslan; P Bracci; S Preston-Martin
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

7.  Hypertension, diuretics and antihypertensives in relation to bladder cancer.

Authors:  Xuejuan Jiang; J Esteban Castelao; Jian-Min Yuan; Susan Groshen; Mariana C Stern; David V Conti; Victoria K Cortessis; Gerhard A Coetzee; Malcolm C Pike; Manuela Gago-Dominguez
Journal:  Carcinogenesis       Date:  2010-08-23       Impact factor: 4.944

8.  CYP1A2, CYP2D6, GSTM1, GSTP1, and GSTT1 gene polymorphisms in patients with bladder cancer in a Turkish population.

Authors:  Ertan Altayli; Sezgin Gunes; Ali Faik Yilmaz; Serdar Goktas; Yuksel Bek
Journal:  Int Urol Nephrol       Date:  2008-08-09       Impact factor: 2.370

9.  Personal use of hair dye and cancer risk in a prospective cohort of Chinese women.

Authors:  Julie Bloch Mendelsohn; Qi-Zhai Li; Bu-Tian Ji; Xiao-Ou Shu; Gong Yang; Hong-Lan Li; Kyoung-Mu Lee; Kai Yu; Nathaniel Rothman; Yu-Tang Gao; Wei Zheng; Wong-Ho Chow
Journal:  Cancer Sci       Date:  2009-03-09       Impact factor: 6.716

10.  Personal use of hair dye and the risk of certain subtypes of non-Hodgkin lymphoma.

Authors:  Yawei Zhang; Silvia De Sanjose; Paige M Bracci; Lindsay M Morton; Rong Wang; Paul Brennan; Patricia Hartge; Paolo Boffetta; Nikolaus Becker; Marc Maynadie; Lenka Foretova; Pierluigi Cocco; Anthony Staines; Theodore Holford; Elizabeth A Holly; Alexandra Nieters; Yolanda Benavente; Leslie Bernstein; Shelia Hoar Zahm; Tongzhang Zheng
Journal:  Am J Epidemiol       Date:  2008-04-11       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.